Replies to post #215938 on Biotech Values

[DewDiligence]

ABBV/Roche—FDA approves Venclexta as addend to Rituxan in second-line CLL/SLL:

https://www.businesswire.com/news/home/20180608005682/en

The PFS hazard ratio for Rituxan/Venclexta vs Rituxan/Treanda was 0.19.